PeptideStack
5.2kquestions
20kanswers
220users

How does survodutide at 7.5 mg weekly compare on cost per milligram across routes?

Asked 13 Sept 2025Modified 6 months agoViewed 7.9k times
19

The case in front of me: survodutide · 7.5 mg.

I want the working, not the result — I need to be able to redo it with different numbers.

I care about the precision as well as the value — I want to know how many figures are real.

Is my approach right even if my number is wrong?

cost-analysis
cost-analysis

Cost arithmetic done honestly: cost per milligram after dead-space loss, list versus net price, comparing a multi-dose vial to a fixed-dose pen,…

260 questions
vendor-comparison
vendor-comparison

Side-by-side comparison of suppliers on measurable axes - independently confirmed purity and content, lead time, cold-chain handling,…

388 questions
dosing-math
dosing-math

The arithmetic itself: milligrams to millilitres to insulin units, concentration after reconstitution, dose per draw, and vial-days per vial. Show…

764 questions
survodutide
survodutide

A GLP-1 and glucagon receptor dual agonist with a substantial published MASH dataset. Use this tag for its hepatic endpoints, its dose ladder, and…

225 questions
shareeditfollowflag
TH
askedthreadlock719k2813 Sept 2025

5 Answers

Accepted answer first, then by votes
109

Accepted answer

7.5 mg a week is 390 mg a year and 32.5 mg in an average month — put every route on that denominator before comparing anything. Cost per milligram is the only figure that survives the comparison, because the presentations differ: a licensed pen prices a dose, a compounding pharmacy prices a vial, and a research supplier prices a mass. Divide each one's twelve-month cost by 390 mg and the three become the same number in the same unit. Then add what the cheapest route does not include — independent purity and content testing, the vials you discard, and the postage — because a route that needs testing to be trustworthy has that testing in its cost per milligram whether you account for it or not.

Start by listing every cost in the chain, since carriage, testing and wastage frequently exceed the difference in headline price.

Dead-space loss is small with fixed-needle insulin syringes — a few microlitres per draw — and substantial with detachable-needle luer syringes at 35 to 100 microlitres. Across twenty draws that is up to two millilitres of solution.

Certificate red flags and what each implies

ObservationImplicationHow to check
Lot number not on the vialCertificate cannot be tied to your materialPhotograph vial and certificate together
No method sectionThe number is not reproducibleRequest column, gradient, wavelength
Purity to two decimals, no chromatogramFalse precisionRequest the trace
Test date before manufacture dateCertificate belongs to a different lotCompare dates
Identical figures across lotsOne certificate reusedCompare two lots side by side
“Sterile filtered” with no sterility testProcess claim substituted for a resultAsk for the sterility report

Worth being precise here: carriage amortises across the order. Twenty-five pounds of carriage on one vial is £2.50/mg on a 10 mg vial; on ten vials it is £0.25/mg. That single term explains most of the case for larger, less frequent orders.

Independent testing prices at the services this community uses are published and are stable enough to model.

Nothing here is medical advice, and research-use compounds are not approved for human use.

Decide whether you are optimising cost or confidence before you build the model.

shareimprove this answerflag
TO
answered · acceptedt_oyelaran79k4815 Sept 2025
4Thank you — this is the answer I was looking for. – plate_count_9k 2 months ago
5I would add a line about writing the accept threshold down first. It is the step everyone skips. – siobhan_deasy 4 months ago
add a comment
Sponsored

Janoshik Analytical - Independent Third-Party Testing

HPLC purity, identity confirmation and quantified content on the vial you actually hold. Reports arrive with the chromatogram attached, not just a number.

Submit a sample
Sponsored — paired listing

GL Biochem (Shanghai) Ltd. - Direct Synthesis

Founded 1998. ISO 9001 and cGMP certified, 1,500+ staff and 200+ patents. The synthesis house behind a great many of the vials that get sent out for testing - batch-specific documentation with every order.

Visit GL Biochem
42

The honest answer is that the cheapest headline price is frequently not the cheapest outcome.

Wastage from a reconstituted vial discarded at the end of its in-use period is a genuine cost, and it is a function of the diluent volume chosen at reconstitution rather than of anything the supplier did.

Cost per milligram is the wrong metric entirely if you are optimising for confidence rather than price, and it is worth saying which one you are doing before you build the spreadsheet.

Larger orders reduce cost per milligram and increase exposure to a single lot, which is a real trade rather than a free win.

Larger orders are cheaper per milligram and concentrate lot risk. Price both.

shareimprove this answerflag
SD
answeredsiobhan_deasy9.5k1526 Sept 2025
2The cost-per-milligram-of-measured-content correction reversed my own spreadsheet. – t_oyelaran 10 months ago
add a comment
31

Answering this needs the order size, because carriage and testing amortise very differently across one vial and across ten.

Change one number and it reverses: if B assays at 82 per cent, that is 8.2 mg for £52, or £6.34/mg, and the cheaper vial is now the more expensive peptide.

Independent testing costs roughly the price of one to two vials at the services this community uses. On a two-vial order that is a fifty to a hundred per cent surcharge; on a twenty-vial order it is five per cent.

Published content assay results across the independent services show nominal and measured content differing by one to ten per cent, which is the term that makes label-price comparisons unreliable.

Divide by measured content, not by label claim. That is the whole correction.

shareimprove this answerflag
DV
answeredDr_Bram_Verhoeven84k24822 Dec 2025
25

Testing cost per milligram falls sharply with order size, which is the main argument against very small repeat orders.

Worked example. Supplier A: £60 for a 10 mg vial, content 96 per cent, so 9.6 mg for £60, or £6.25/mg before carriage. Supplier B: £52 for the same nominal vial, content 88 per cent, so 8.8 mg for £52, or £5.91/mg. B still wins here, but the gap has narrowed from thirteen per cent on the label to five per cent in reality.

A spreadsheet built on label claim rather than measured content is precise about the wrong number.

Fixed-needle syringes save more peptide than most price differences do.

edited 29 Jan 2026 by t_oyelaran — clarified the distinction between purity and content

shareimprove this answerflag
TO
answeredt_oyelaran79k482 Jan 2026
24

This is a spreadsheet question and doing it properly changes conclusions more often than people expect.

The full calculation: (unit price + carriage share + testing share) ÷ (nominal mg × measured content fraction × (1 − dead-space and wastage fraction)). Every term after the first is routinely omitted.

Include carriage and testing as per-milligram terms. They dominate small orders.

edited 15 Dec 2025 by w_okoye — added a caveat about sampling

shareimprove this answerflag
WO
answeredw_okoye43k13730 Nov 2025
2I have kept every invoice and declaration, which I gather is the useful habit. – Dr_Colm_Fitzhenry 8 months ago
3Small correction: carriage amortises across the order, which changes small-order economics entirely. – pieter_maas 9 months ago
add a comment

Your answer

Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.

Not medical advice. Research-use-only compounds are not approved for human use.